Investor Relations

Corporate Profile

We are a clinical stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical need. Our current focus is on advancing our lead program AKR-001 to provide a powerful new treatment for patients with NASH, a disease for which there are currently no marketed therapies.

Copyright West LLC. Minimum 15 minutes delayed.

Recent News

September 4, 2019

Akero Therapeutics To Present At The Morgan Stanley 17th Annual Global Healthcare Conference

SAN FRANCISCO , Sept. 4, 2019 /PRNewswire/ --  Akero Therapeutics, Inc.  (Nasdaq: AKRO), a clinical-...

August 12, 2019

Akero Therapeutics Reports Recent Highlights and Second Quarter 2019 Financial Results

-- Advanced AKR-001 into Phase 2a BALANCED clinical study in NASH -- -- Raised $98.4 million in aggr...

July 2, 2019

Akero Therapeutics Announces Dosing of First Patient in Phase 2a Study of AKR-001 to Treat NASH (BALANCED)

SAN FRANCISCO , July 2, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-sta...

June 24, 2019

Akero Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

SAN FRANCISCO , June 24, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-st...

June 19, 2019

Akero Therapeutics Announces Pricing of Initial Public Offering

SAN FRANCISCO , June 19, 2019 /PRNewswire/ --  Akero Therapeutics, Inc. (NASDAQ: AKRO), a clinical-s...

May 29, 2019

Akero Therapeutics Initiates Phase 2a Clinical Trial of Investigational Therapy AKR-001 for the Treatment of NASH

SAN FRANCISCO, May 29, 2019 /PRNewswire/ -- Akero Therapeutics, Inc., a biotechnology company develo...